SCHEMBL5136840

SCHEMBL5136840

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.39
TSHR P16473 3/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 2/20 0.38
LMNA P02545 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
DHFR P00374 3/20 0.37
MMP13 P45452 1/20 0.37
BCHE P06276 3/20 0.36
HSD17B10 Q99714 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
CNR2 P34972 1/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5138032 0.95 C5AR1 (0.43) C5AR1TRPM8TSHRPPARGPPARA
SCHEMBL5135486 0.93 C5AR1 (0.42) C5AR1PPARGPPARAMMP13CRHR1
SCHEMBL651365 0.92 C5AR1 (0.46) C5AR1TSHRKDM4EALDH1A1GAA
SCHEMBL5136018 0.92 C5AR1 (0.41) C5AR1TRPM8TSHRPPARGPPARA
SCHEMBL5137638 0.92 C5AR1 (0.41) C5AR1TRPM8TSHRPPARGPPARA
SCHEMBL5136208 0.92 CRHR1 (0.43) C5AR1TRPM8TSHRPPARGPPARA
SCHEMBL5137466 0.92 DHFR (0.42) C5AR1TSHRKDM4EALDH1A1GAA
SCHEMBL5136185 0.92 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1GAA
SCHEMBL5072205 0.92 C5AR1 (0.46) C5AR1TSHRKDM4EALDH1A1GAA
SCHEMBL5136291 0.91 C5AR1 (0.45) C5AR1TSHRKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed